Ozempic vs. Wegovy vs. Mounjaro: Costs, Coverage, and Key Differences

Three names keep coming up in conversations about weight loss medications: Ozempic, Wegovy, and Mounjaro. They're related — but they're not the same drug, they're not approved for the same purposes, and they don't cost the same or get covered the same way by insurance. Here's what you actually need to know to have an informed conversation with your doctor and your insurer.

What These Drugs Are — and How They Work

All three belong to a class of medications that mimic hormones involved in blood sugar regulation and appetite control. The key difference is which hormones they target.

• Ozempic (semaglutide) is a GLP-1 receptor agonist. It was FDA-approved for type 2 diabetes management. It works by stimulating insulin release, slowing digestion, and reducing appetite. Weight loss is a well-documented side effect, but it is not the drug's approved indication.

• Wegovy (also semaglutide) contains the same active ingredient as Ozempic but at a higher approved dose. It is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. This distinction — approved use — matters enormously for insurance coverage.

• Mounjaro (tirzepatide) targets two hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). It was FDA-approved for type 2 diabetes. Its sister drug, Zepbound (same active ingredient, tirzepatide), is the version FDA-approved for chronic weight management. Mounjaro and Zepbound are to tirzepatide what Ozempic and Wegovy are to semaglutide.

The dual-hormone mechanism in tirzepatide has shown strong results in clinical trials, but comparing outcomes across individual patients is complicated by many personal health factors.

Approved Use vs. Off-Label Prescribing 💊

This is one of the most important distinctions for anyone navigating these medications.

Prescribing Ozempic or Mounjaro off-label for weight loss is legal and medically common — but it affects insurance coverage significantly. Insurers typically cover drugs for their approved indications. If you're prescribed Ozempic for weight loss rather than diabetes, coverage may be denied or more difficult to obtain.

What These Medications Typically Cost — and Why It Varies So Much

Without insurance, all three of these drugs carry high list prices — often running into hundreds of dollars per month per prescription. Exact prices shift based on pharmacy, dosage, location, and manufacturer pricing changes, so any specific figure stated here could be outdated quickly. What matters is understanding the factors that affect what you'd actually pay:

Factors that affect your out-of-pocket cost:

• Insurance coverage: Whether your plan covers the specific drug at all, and under what tier, is the single biggest variable. Many commercial plans cover Ozempic for diabetes but explicitly exclude weight loss drugs. Medicare Part D has historically excluded weight loss medications, though policy discussions continue to evolve.
• Your specific plan's formulary: Even within the same insurer, plans vary. A drug covered under one employer's plan may not be covered under another's.
• Prior authorization requirements: Most insurers require documented medical necessity before approving these drugs. Requirements differ by drug and diagnosis.
• Manufacturer savings programs: Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) have offered savings cards or patient assistance programs, but eligibility typically excludes government insurance like Medicare and Medicaid.
• Pharmacy benefit vs. medical benefit: In some cases, how your insurance processes the claim affects your cost.
• Compounded versions: During drug shortages, compounding pharmacies have produced versions of semaglutide and tirzepatide, often at lower prices. These are not FDA-approved products and come with different risk and quality considerations.

Insurance Coverage: The Landscape 🗺️

Coverage for these medications is genuinely uneven, and this is one of the most consequential things to understand before assuming a prescription is affordable.

Diabetes diagnosis changes the picture. Ozempic and Mounjaro have broader insurance coverage because they're prescribed for a condition (type 2 diabetes) that insurers routinely cover. If you have both diabetes and obesity, coverage pathways are more accessible.

Weight-loss-only coverage is limited but growing. Wegovy and Zepbound are approved weight management drugs, but many commercial insurers and most government programs have historically excluded weight loss medications from formularies. Some large employers and certain state Medicaid programs have begun adding coverage, but this is inconsistent nationwide.

Medicare Part D has traditionally excluded coverage for weight loss drugs. Legislative changes have been proposed, and the landscape may shift — but at the time of writing, Medicare coverage for weight management medications like Wegovy and Zepbound remains limited and contingent on specific qualifying conditions.

What to check with your insurer:

• Is the specific drug (by name and NDC code) on your formulary?
• What tier is it, and what is the cost-sharing?
• Are there prior authorization criteria, and what documentation is required?
• Does your plan have a step therapy requirement (trying another drug first)?

Key Differences That Matter When Comparing These Drugs

Beyond approval status and cost, a few clinical differences are worth understanding — while recognizing that drug selection is a medical decision.

Semaglutide vs. tirzepatide: These are different molecules with different mechanisms. Tirzepatide's dual-action (GLP-1 + GIP) produced stronger average weight loss results in clinical trials compared to semaglutide-based trials, but direct head-to-head trials in weight management contexts have been limited, and individual responses vary meaningfully.

Dosing and titration: Both drug classes use gradual dose escalation to reduce side effects (primarily nausea, vomiting, and GI discomfort). The titration schedules differ between products.

Administration: All three are injectable medications given weekly via a self-administered pen. None are pills (though oral semaglutide exists for diabetes under the brand Rybelsus).

Side effect profiles: GI side effects are common to all three. Serious but rare risks — including pancreatitis and, based on animal studies, thyroid concerns — are noted in prescribing information and warrant discussion with a physician.

What Your Decision Actually Depends On

No article can tell you which of these medications, if any, is right for you. What it can tell you is what to bring to that conversation: ⚕️

• Your diagnosis: Diabetes, obesity, both, or neither changes which drugs are indicated and which are likely covered.
• Your insurance plan specifics: The same drug can cost very different amounts depending on your coverage.
• Your medical history: Contraindications, existing conditions, and prior medication use all factor into prescribing decisions.
• Your goals and preferences: Weight loss magnitude, tolerability, cost sustainability, and long-term plans are all relevant to which option a provider might recommend.

The medications work similarly in mechanism, differ in molecule and approved use, and vary widely in what they'll actually cost you — and that last part is impossible to determine without knowing your specific plan.